Clinical ScienceThe role of diabetes and other co-morbidities on survival after esophageal cancer surgery in a population-based study
Section snippets
Study design
This was a nationwide, Swedish, population-based prospective cohort study of patients diagnosed with esophageal or esophagogastric junctional cancer who underwent curative esophageal resection from April 2, 2001, to December 31, 2005, with follow-up until death or the end of the study period (May 31, 2011). Informed consent was obtained from all participating patients, and the Regional Ethical Review Board in Stockholm, Sweden, approved the study.
Data collection
Data were collected from the prospective Swedish
Patient characteristics
A total of 616 patients were included in the database, representing 90% of all eligible patients in the study base. Because of missing data on tumor stage in 6 patients and missing histology in 1 patient, the final analyses were performed on 609 patients (99%). Characteristics of patients with and without diabetes and other comorbidities are presented in Table 1. Diabetes was found in 67 patients (11%). Patients with diabetes were older than those without comorbidities. Also, patients with
Comments
This study indicates that neither the presence of diabetes nor the comorbidities of cardiovascular disease, hypertension, and pulmonary disease increase mortality after esophageal cancer surgery.
Diabetes has recently been reported to increase the risk for mortality in patients with cancer in general14 and after colorectal cancer surgery in particular.15, 16 Two previous studies have found that the presence of diabetes is associated with an increased risk for 30-day mortality after esophageal
References (20)
- et al.
Survival after surgery for oesophageal cancer: a population-based study
Lancet Oncol
(2005) - et al.
Outcomes after esophagectomy: a ten-year prospective cohort
Ann Thorac Surg
(2003) - et al.
The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma
J Am Coll Surg
(2004) - et al.
IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030
Diabetes Res Clin Pract
(2011) - et al.
Outcome of esophagectomy for cancer in elderly patients
Ann Thorac Surg
(2010) - et al.
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Int J Cancer
(2010) - et al.
Diverging trends in recent population-based survival rates in oesophageal and gastric cancer
PLoS One
(2012) - et al.
Oesophageal cancer
BMJ
(2010) - et al.
Underuse of esophagectomy as treatment for resectable esophageal cancer
Arch Surg
(2008) - et al.
Prognostic importance of comorbidity in a hospital-based cancer registry
JAMA
(2004)
Cited by (17)
Surgical and long-term outcomes following oesophagectomy in oesophageal cancer patients with comorbidity
2016, International Journal of SurgeryCitation Excerpt :This result is identical to those of previous studies [27,29]. In contrast, Backemar et al. showed that comorbidity had no association with OS in oesophageal cancer [30]. In their study, 16% of the patients had undergone only a gastrectomy instead of an oesophageal resection.
Complex Esophageal Reconstruction Procedures Have Acceptable Outcomes Compared with Routine Esophagectomy
2016, Annals of Thoracic SurgeryDoes diabetes mellitus have an impact on the prognosis for patients with cervical cancer?
2015, Gynecologic OncologyCitation Excerpt :However, some studies could not show any negative effect of DM on the prognosis for patients with several other cancers, as in the present study. Backemar et al. found that among 609 patients with esophageal or cardia cancer, 67 with DM had no increased risk for mortality compared with those without DM (HR, 0.81; 95% CI, 0.60–1.09) [17]. Suer et al. evaluated the prognostic value of DM among patients with renal cell carcinoma and could not detect DM as an independent prognostic factor for this tumor [18].
Diabetes, metformin use, and survival in esophageal cancer: a population-based cohort study
2023, JNCI Cancer Spectrum
This project was funded by the Swedish Cancer Society, the Swedish Research Council, the Swedish National Board of Health and Welfare, and the Swedish Society of Medicine.
The authors declare no conflicts of interest.